Page last updated: 2024-12-09

tram 34

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TRAM 34: inhibits IKCa1; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID656734
CHEMBL ID498270
CHEBI ID34990
SCHEMBL ID41130
MeSH IDM0367390

Synonyms (39)

Synonym
1-[(2-chlorophenyl)-di(phenyl)methyl]pyrazole
gtpl2336
tram-34
1-[(2-chlorophenyl)diphenylmethyl]-1h-pyrazole
c22h17cln2
NCGC00165909-01
NCGC00165909-02
tram 34
chebi:34990 ,
CHEMBL498270 ,
AKOS005146304
FT-0651467
1-((2-chlorophenyl)diphenylmethyl)-1h-pyrazole
bdbm50279107
AC1LCVHZ ,
1-[(2-chlorophenyl)-diphenylmethyl]pyrazole
tram34
289905-88-0
1h-pyrazole, 1-[(2-chlorophenyl)diphenylmethyl]-
NCGC00165909-03
S1160
HY-13519
CS-1921
SCHEMBL41130
DS-2617
HB1058
AC-33068
surecn41130
1-[(2-chlorophenyl)-diphenyl-methyl]pyrazole
mfcd09842562
DTXSID70349650
triarylmethane-34
tram-34, >=98% (hplc), solid
J-017347
EX-A2316
Q27089017
BCP01324
AMY36456
HMS3748M21

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Therapeutic concentrations of TRAM-34 in mice caused no discernible toxicity after repeated dosing and did not compromise the immune response to influenza virus."( The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
Azam, P; Chandy, KG; Das, S; Fujiwara, Y; Gutterman, DD; Harder, DR; Hatoum, OA; Mattson, DL; Melvin, JE; Miura, H; Pratt, PF; Raman, G; Saito, T; Toyama, K; Wulff, H, 2008
)
0.35
" Uterine arteries maintained at constant intramural pressure (90 mm Hg) were maximally constricted with thromboxane, and a dose-response for acetylcholine (Ach) was recorded."( Mechanisms Underlying Chronic Binge Alcohol Exposure-Induced Uterine Artery Dysfunction in Pregnant Rat.
Davis-Anderson, K; Lunde-Young, R; Naik, VD; Nemec, MJ; Ramadoss, J; Subramanian, K, 2018
)
0.48
" Subsequently, a dose-response was recorded following inhibition of endothelium-derived hyperpolarizing factor (apamin and TRAM-34) and prostacyclin (indomethacin)."( Mechanisms Underlying Chronic Binge Alcohol Exposure-Induced Uterine Artery Dysfunction in Pregnant Rat.
Davis-Anderson, K; Lunde-Young, R; Naik, VD; Nemec, MJ; Ramadoss, J; Subramanian, K, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency1.02050.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Intermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)IC50 (µMol)0.02000.00600.07970.3600AID397426; AID397428
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)IC50 (µMol)5.00000.00203.19698.0000AID397423
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
immune system processIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
potassium ion transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calcium ion transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
cell volume homeostasisIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
defense responseIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
stabilization of membrane potentialIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
phospholipid translocationIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
saliva secretionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of protein secretionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
establishment of localization in cellIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
positive regulation of potassium ion transmembrane transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
potassium ion transmembrane transportIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
protein bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
small conductance calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
protein phosphatase bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
calmodulin bindingIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
intermediate conductance calcium-activated potassium channel activityIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
voltage-gated monoatomic ion channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
cytosolIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
plasma membraneIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
vesicleIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
voltage-gated potassium channel complexIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
plasma membraneIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
neuronal cell bodyIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
neuron projectionIntermediate conductance calcium-activated potassium channel protein 4Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
axonPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID397426Inhibition of human cloned IK1 expressed in african green monkey COS7 cells by whole cell patch clamp assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID397437Immunosuppressant activity in human effector memory T cells of PBMC assessed as inhibition of anti-CD3 antibody-induced cell proliferation by ELISA in presence of 5 uM Kv1.3-blocker PAP12009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID397429Inhibition of human HaCaT cell proliferation after 48 hrs2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID397431Immunosuppressant activity in human effector memory T cells of PBMC assessed as inhibition of anti-CD3 antibody-induced cell proliferation by ELISA2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID397428Inhibition of IK12009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID397423Inhibition of cloned Kv1.3 channel expressed in mammalian cells by whole cell patch clamp assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)2003Circulation, Sep-02, Volume: 108, Issue:9
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis.
AID1346444Human KCa3.1 (Calcium- and sodium-activated potassium channels)2000Proceedings of the National Academy of Sciences of the United States of America, 07-05, Volume: 97, Issue:14
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (207)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's50 (24.15)29.6817
2010's142 (68.60)24.3611
2020's15 (7.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.88 (24.57)
Research Supply Index5.35 (2.92)
Research Growth Index6.34 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.48%)5.53%
Reviews3 (1.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other204 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]